When I stood before the white door of the clinic, holding my medical checkup appointment slip, I had a premonition that I was ...

GSK has secured US FDA approval for Hibsago in chronic hepatitis B, a first-in-class treatment designed to help patients achieve a functional cure.

Fatty liver disease is characterized by the accumulation of triglycerides—a type of fat—in the liver. The disease has a ...

Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and enabled considerable therapeutic advances for ...

At 4.8 mg/kg, one under-the-skin dose cleared more than 90% of the target antibody in mice within two hours; depletion lasted ...

A longitudinal cohort study of 60 patients at a Western Kenyan referral hospital found earlier changes in kidney-function ...

Plus: Palmer Luckey’s new startup plans to genetically enhance military dogs.

GSK wins FDA approval for Hibsago, a first-in-class hepatitis B therapy. Learn how this and a new Jemperli indication shape the company’s specialty growth outlook.

Crowd-sourced control systems—in which distributed participants collectively steer a shared agent through real-time voting—are formalized in robotics as Multi-Operator Single-Robot (MOSR) ...

Drugmakers have spent decades searching for molecules that act on specific disease targets. That strategy has produced blockbuster medicines, but it has also left researchers struggling with ...

A near-infrared fluorescent choline kinase α inhibitor, JAS239, was used to identify tumors in canine patients.